-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, a research article was published in Heart, an authoritative journal in the field of cardiology.
Digestion
The researchers conducted a cohort study using a general protocol and a general data model method.
The study included 164,290 AF patients receiving NOAC treatment, and 272,570 annual follow-ups were conducted.
The incidence ratio of UGIB in each subgroup
The subjects are divided into ages 75-84 years (the number of people who need treatment for 1 year (NNTY) is 787), the age is ≥85 years (NNTY is 667), and the HAS-BLED score is ≥3 (NNTY is 378) or Concomitant antiplatelet therapy (373 people with NNTY) has the greatest protective effect in high-risk patients
It can be seen that the simultaneous use of PPI in AF patients receiving NOAC treatment is associated with a reduction in the risk of severe UGIB
Concurrent use of PPI in AF patients treated with NOAC is associated with a reduced risk of severe UGIB
Original source:
Joris Komen.
Non-vitamin K antagonist oral anticoagulants, proton pump inhibitors and gastrointestinal bleeds
in this message